Satoshi Kudoh

4.1k total citations
156 papers, 3.5k citations indexed

About

Satoshi Kudoh is a scholar working on Atomic and Molecular Physics, and Optics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Satoshi Kudoh has authored 156 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Atomic and Molecular Physics, and Optics, 46 papers in Oncology and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Satoshi Kudoh's work include Advanced Chemical Physics Studies (57 papers), Lung Cancer Treatments and Mutations (33 papers) and Lung Cancer Research Studies (30 papers). Satoshi Kudoh is often cited by papers focused on Advanced Chemical Physics Studies (57 papers), Lung Cancer Treatments and Mutations (33 papers) and Lung Cancer Research Studies (30 papers). Satoshi Kudoh collaborates with scholars based in Japan, United States and Netherlands. Satoshi Kudoh's co-authors include Munetaka Nakata, M. Takayanagi, Fumitaka Mafuné, M. Fukuoka, Nobuyuki Akai, Taku Komura, Kunihiko Matsui, Shunichi Negoro, K. Hirata and Ken Miyajima and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Carbon.

In The Last Decade

Satoshi Kudoh

152 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satoshi Kudoh Japan 32 1.2k 1.1k 744 721 530 156 3.5k
Zhongli Cai Canada 32 467 0.4× 1.1k 1.0× 633 0.9× 1.3k 1.8× 365 0.7× 86 4.1k
Paul Schaffer Canada 38 663 0.5× 1.0k 0.9× 195 0.3× 642 0.9× 887 1.7× 199 5.1k
Hiroshi Fujimoto Japan 40 643 0.5× 296 0.3× 932 1.3× 975 1.4× 713 1.3× 269 6.3k
Osamu Kikuchi Japan 28 373 0.3× 245 0.2× 633 0.9× 773 1.1× 332 0.6× 237 3.2k
Nobuyuki Nakajima Japan 46 1.1k 0.9× 1.5k 1.4× 248 0.3× 1.7k 2.3× 428 0.8× 364 7.1k
Hiroaki Shimizu Japan 29 340 0.3× 409 0.4× 495 0.7× 170 0.2× 726 1.4× 204 2.8k
Arnab Mukherjee India 28 381 0.3× 253 0.2× 134 0.2× 1.2k 1.6× 273 0.5× 106 3.6k
Michio Kobayashi Japan 31 711 0.6× 430 0.4× 113 0.2× 852 1.2× 324 0.6× 383 5.0k
Alberto Marini Italy 25 351 0.3× 163 0.1× 195 0.3× 950 1.3× 479 0.9× 88 2.5k
Kazuhiko Shibuya Japan 29 248 0.2× 161 0.1× 817 1.1× 114 0.2× 504 1.0× 162 3.0k

Countries citing papers authored by Satoshi Kudoh

Since Specialization
Citations

This map shows the geographic impact of Satoshi Kudoh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Kudoh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Kudoh more than expected).

Fields of papers citing papers by Satoshi Kudoh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Kudoh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Kudoh. The network helps show where Satoshi Kudoh may publish in the future.

Co-authorship network of co-authors of Satoshi Kudoh

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Kudoh. A scholar is included among the top collaborators of Satoshi Kudoh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Kudoh. Satoshi Kudoh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kabata, Daijiro, Tomoko Sakaguchi, Satoshi Kudoh, et al.. (2018). Usefulness of serum biopterin as a predictive biomarker for childhood asthma control: A prospective cohort study. Allergology International. 68(1). 96–100. 3 indexed citations
3.
4.
Okada, Yoshiki, et al.. (2011). Accuracy of Nanoparticle Diameters Measured with a Differential Mobility Analyzer in Free-Molecule Regime. 26(3). 242–246. 1 indexed citations
5.
Fukuoka, M., Satoshi Kudoh, Ken Nakagawa, et al.. (2011). Post-marketing surveillance of erlotinib for NSCLC in Japan: Interim analyses of 3,488 patients (Pts).. Journal of Clinical Oncology. 29(15_suppl). e18007–e18007. 1 indexed citations
6.
Takeda, Koji, Shunichi Negoro, Tomohide Tamura, et al.. (2009). Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Annals of Oncology. 20(5). 835–841. 57 indexed citations
7.
Kudoh, Satoshi, Taku Komura, & Koji IKEUCHI. (2006). Robotics and Automation, 2006. ICRA 2006. Proceedings 2006 IEEE International Conference on. 118 indexed citations
8.
Nakagawa, Kazuhiko, Satoshi Kudoh, Kunihiko Matsui, et al.. (2006). A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. British Journal of Cancer. 95(6). 677–682. 52 indexed citations
9.
Kudoh, Satoshi, Satoaki Nakamura, Takashi Nakano, et al.. (2005). Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: A phase II trial of West Japan Thoracic Oncology Group. Lung Cancer. 49(2). 263–269. 11 indexed citations
10.
Yoshimura, Naruo, Satoshi Kudoh, Toru Mukohara, et al.. (2004). Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer. British Journal of Cancer. 90(6). 1184–1189. 8 indexed citations
11.
Negoro, Shunichi, N Masuda, Y Takada, et al.. (2003). Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. British Journal of Cancer. 88(3). 335–341. 121 indexed citations
12.
Kawahara, Minoru, Kiyoyuki Furuse, Yoshihiko Segawa, et al.. (2001). Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. British Journal of Cancer. 85(7). 939–943. 188 indexed citations
13.
Matsui, K, N Masuda, M. Fukuoka, et al.. (1998). Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. British Journal of Cancer. 77(11). 1961–1965. 39 indexed citations
14.
Kudoh, Satoshi, Yasuhiro Fujiwara, Y Takada, et al.. (1998). Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.. Journal of Clinical Oncology. 16(3). 1068–1074. 139 indexed citations
15.
Kanazawa, Hiroshi, Takashi Kawaguchi, Takashi Fujii, et al.. (1997). Synergistic Effect of Nitric Oxide and Vasoactive Intestinal Peptide on Bronchoprotection Against Histamine in Anesthetized Guinea Pigs. American Journal of Respiratory and Critical Care Medicine. 155(2). 747–750. 18 indexed citations
16.
Fukuoka, M., N Masuda, Shunichi Negoro, et al.. (1997). CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. British Journal of Cancer. 75(2). 306–309. 37 indexed citations
17.
Kudoh, Satoshi, Toshiyuki Sawa, Naotsugu Kurihara, et al.. (1996). Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 38(0). S89–S95. 5 indexed citations
18.
Masuda, N, M. Fukuoka, Satoshi Kudoh, et al.. (1994). Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 12(1). 90–96. 78 indexed citations
19.
Masuda, N, M. Fukuoka, M Takada, et al.. (1992). CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 10(11). 1775–1780. 130 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhongli Cai Breakdown of academic impact, for papers by Paul Schaffer Breakdown of academic impact, for papers by Hiroshi Fujimoto Breakdown of academic impact, for papers by Osamu Kikuchi Breakdown of academic impact, for papers by Nobuyuki Nakajima Breakdown of academic impact, for papers by Hiroaki Shimizu Breakdown of academic impact, for papers by Arnab Mukherjee Breakdown of academic impact, for papers by Michio Kobayashi Breakdown of academic impact, for papers by Alberto Marini Breakdown of academic impact, for papers by Kazuhiko Shibuya
Rankless by CCL
2026